HROW Harrow Health Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HROW

Price (delayed)

$34.83

Market cap

$1.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.39

Enterprise value

$1.5B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 54

Harrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton ...

Highlights
Harrow Health's quick ratio has soared by 178% YoY and by 12% from the previous quarter
HROW's revenue is up by 26% year-on-year
Harrow Health's net income has plunged by 191% from the previous quarter but it has increased by 31% YoY
The EPS has dropped by 179% since the previous quarter but it rose by 36% year-on-year
Harrow Health's equity has decreased by 49% YoY and by 45% from the previous quarter
Harrow Health's debt has increased by 31% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.harrowinc.com
Peers: OPK ORGO

Key stats

What are the main financial stats of HROW

HROW stock price

How has the Harrow Health stock price performed over time
Intraday
4.53%
1 week
-1.58%
1 month
-13.36%
1 year
18.03%
YTD
-28.92%
QTD
-1.22%

Financial performance

How have Harrow Health's revenue and profit performed over time
Revenue
$268.68M
Gross profit
$199.11M
Operating income
$19.67M
Net income
-$14.96M
Gross margin
74.1%
Net margin
-5.6%
Harrow Health's net margin has plunged by 195% from the previous quarter but it has increased by 45% YoY
Harrow Health's net income has plunged by 191% from the previous quarter but it has increased by 31% YoY
Harrow Health's operating income has decreased by 36% from the previous quarter
HROW's operating margin is down by 35% since the previous quarter

Price vs fundamentals

How does HROW's price correlate with its fundamentals

Growth

What is Harrow Health's growth rate over time

Valuation

What is Harrow Health stock price valuation
P/E
N/A
P/B
45.17
P/S
4.83
EV/EBIT
125.74
EV/EBITDA
46.27
EV/Sales
5.6
The EPS has dropped by 179% since the previous quarter but it rose by 36% year-on-year
Harrow Health's equity has decreased by 49% YoY and by 45% from the previous quarter
The stock's price to book (P/B) is 29% more than its 5-year quarterly average of 33.6 and 23% more than its last 4 quarters average of 35.2
HROW's revenue is up by 26% year-on-year
HROW's P/S is 22% below its last 4 quarters average of 5.9 and 3.8% below its 5-year quarterly average of 4.8

Efficiency

How efficient is Harrow Health business performance
The return on assets has dropped by 179% since the previous quarter but it is up by 36% year-on-year
The ROIC has plunged by 58% from the previous quarter
The return on sales has declined by 46% since the previous quarter
Harrow Health's return on equity has increased by 6% YoY

Dividends

What is HROW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HROW.

Financial health

How did Harrow Health financials performed over time
The total assets is 7% greater than the total liabilities
Harrow Health's quick ratio has soared by 178% YoY and by 12% from the previous quarter
Harrow Health's current ratio has surged by 173% YoY and by 13% QoQ
The debt to equity has soared by 157% YoY and by 118% from the previous quarter
Harrow Health's equity has decreased by 49% YoY and by 45% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.